This year’s Annual Meeting was held live in Boston, USA, from 22-28 April, with delegates meeting in person and online for presentations on the latest clinical and scientific data including research on anti-CGRP therapies.
Taking ubrogepant 100 mg during the prodromal phase of migraine can prevent the onset of moderate or severe headache and reduce functional disability.1-3 Primary endpoint data from 477 qualifying patients in the PRODROME study showed that in 45.5% of ubrogepant-treated qualifying prodrome events, moderate/severe intensity headache was absent within 24 hours.1 This compared with 28.6% …
Read more »Atogepant 60 mg once daily (QD) significantly reduces mean monthly migraine days (MMDs) in patients with episodic migraine who have failed previous preventive therapies, according to data from the Phase 3 ELEVATE trial.1 Of 309 adults enrolled in the study, 56% had previously failed two classes of oral migraine preventive medications due to lack of …
Read more »Pooled zavegepant data from two randomised, placebo-controlled trials with over 2000 patients (NCT03872453, NCT04571060) show that the gepant nasal spray relieves migraine irrespective of attack frequency and whether or not patients experience aura.1,2 In patients experiencing fewer than four migraine attacks per month during the three months prior to study entry, 24.0% of patients using …
Read more »At least one in five patients treated with erenumab at a tertiary US headache department between 2018 and 2021 had worsening of blood pressure as defined by American Heart Association guidance. Of 335 patients, 70 (20.9%) had pre-existing hypertension at baseline. After a mean 30.6 weeks follow-up, 78/335 (23.3%) of all patients had worsening of …
Read more »Real world fremanezumab data and clinical trial results for eptinezumab show no evidence of ‘wearing off’ with either agent.1,2 A retrospective, observational US healthcare claims analysis of 3217 monthly dosing cycles in adult patients with at least two fremanezumab monthly claims showed no increase in migraine-related health care resource use (HCRU) or acute medication use …
Read more »Gepants may be an effective acute treatment for migraine in paediatric patients and appear safe and well-tolerated, though larger prospective, randomised trials are needed, conclude researchers who carried out a retrospective chart review of 13 patients under 18 who were prescribed rimegepant or ubrogepant for acute migraine at a single institution from January 2020 to …
Read more »Non-ictal allodynia has been shown to predict galcanezumab responders with nearly 80% accuracy, and galcanezumab non-responders with nearly 85% accuracy. Quantitative sensory testing was used to detect the presence or absence of cephalic and/or extracephalic allodynia during the pre-treatment non-ictal phase of migraine, with allodynia criteria of <40 degrees C for heat, >20 degrees C …
Read more »Immunisation with UB-313, a vaccine designed to stimulate production of endogenous CGRP antibodies, has induced a robust antibody response in preclinical studies. Affinity purified antibodies from immunised animals bound to human CGRP with high affinity (KD in the low pM range) and showed a dose-dependent functional inhibition of CGRP (EC50 in the low nM range) …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
